Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
What does it do?
Vertex makes medicines for rare, serious diseases that most drug companies ignore. Their biggest focus is cystic fibrosis, a genetic condition that clogs the lungs with thick mucus and affects about 90,000 people worldwide. Their flagship drug, Trikafta, doesn't just treat symptoms — it fixes the underlying protein defect that causes the disease. More recently, they won approval for a gene therapy called Casgevy, co-developed with CRISPR Therapeutics, that can functionally cure sickle cell disease.
Vertex has done something almost no biotech company has managed: it essentially owns a disease. Over 90% of CF patients are eligible for their drugs, and there is no serious competitor on the market, making this one of the most durable monopolies in medicine. On top of that, their new gene therapy for sickle cell disease opens a door to a completely new category of medicine — one-time cures — that could redefine how the industry values biotech companies.
How does it make money?
Vertex generates almost all of its $12 billion in annual revenue from selling CF medicines, primarily Trikafta and its newer version Alyftrek, to patients in the US, Europe, and internationally. Revenue grew roughly 9% year-over-year from $11 billion to $12 billion, driven by expanding patient access and new age approvals bringing younger children onto therapy. Net income came in at $4 billion, meaning Vertex keeps about 33 cents of profit for every dollar it earns — a sign of a highly efficient, low-competition business. Casgevy, their sickle cell cure priced at $2.2 million per patient, is in early commercial rollout and not yet a major revenue driver.
Why do investors care?
The core growth story is defending and expanding the CF franchise while using that cash to fund the next big thing. Vertex has a deep pipeline targeting kidney disease, Type 1 diabetes, and pain — markets that are vastly larger than CF. Their non-opioid pain drug suzetrigine received FDA approval in early 2025 and could be a blockbuster if doctors adopt it widely. For the thesis to work, the pipeline needs to deliver: at least one or two of these new drugs needs to become a major revenue contributor before the CF patent cliff — when generic competitors can potentially enter — becomes a real threat.
Deep Dive
MemberA full investor briefing on Vertex Pharmaceuticals Incorporated — history, leadership, risks, and outlook.